INHIBITORY EFFECTS OF SUBSTRATE-BASED BCR-ABL1 KINASE INHIBITORS ON THE GROWTH OF CHRONIC MYELOID LEUKEMIA CELL LINE K562

被引：0
|
作者：
Huang, Y. -H. [1 ]
Henriques, S. Troeira [1 ]
Lawrence, N. [1 ]
Kaas, Q. [1 ]
Craik, D. J. [1 ]
机构：
[1] Univ Queensland, Inst Mol Biosci, Brisbane, Qld, Australia
来源：
JOURNAL OF PEPTIDE SCIENCE | 2016年 / 22卷
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
PP IX-257
引用
收藏
页码：S174 / S174
页数：1
相关论文
共 50 条
  • [21] β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia
    A M Eiring
    J S Khorashad
    D J Anderson
    F Yu
    H M Redwine
    C C Mason
    K R Reynolds
    P M Clair
    K C Gantz
    T Y Zhang
    A D Pomicter
    I L Kraft
    A D Bowler
    K Johnson
    M Mac Partlin
    T O'Hare
    M W Deininger
    Leukemia, 2015, 29 : 2328 - 2337
  • [22] A Novel BCR-ABL1 Degrader, Ubx-362, Can Overcome Resistance By BCR-ABL1 Kinase Domain Mutations in Chronic Myeloid Leukemia
    Lim, Ye Seul
    Jeong, Na-Rae
    Yoo, Sun-Mi
    Kim, Han Wool
    Lee, Song Hee
    Kim, Dong-Wook
    BLOOD, 2023, 142
  • [23] Mutational analysis of tyrosine kinase domain of BCR-ABL1 gene in chronic myeloid leukemia patients resistant to tyrosine kinase inhibitors
    Kihel, I.
    Nachi, M.
    Cayuela, J.
    Bekadja, M. A.
    Note, A.
    CLINICA CHIMICA ACTA, 2024, 558
  • [24] Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia
    Dakota Gustafson
    Jason E. Fish
    Jeffrey H. Lipton
    Nazanin Aghel
    Current Hematologic Malignancy Reports, 2020, 15 : 20 - 30
  • [25] Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia
    Gustafson, Dakota
    Fish, Jason E.
    Lipton, Jeffrey H.
    Aghel, Nazanin
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2020, 15 (01) : 20 - 30
  • [26] Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors
    Kim, Sung-Hyun
    Menon, Hari
    Jootar, Saengsuree
    Saikia, Tapan
    Kwak, Jae-Yong
    Sohn, Sang-Kyun
    Park, Joon Seong
    Jeong, Seong Hyun
    Kim, Hyeoung Joon
    Kim, Yeo-Kyeoung
    Oh, Suk Joong
    Kim, Hawk
    Zang, Dae Young
    Chung, Joo Seop
    Shin, Ho Jin
    Do, Young Rok
    Kim, Jeong-A
    Kim, Dae-Young
    Choi, Chul Won
    Park, Sahee
    Park, Hye Lin
    Lee, Gong Yeal
    Cho, Dae Jin
    Shin, Jae Soo
    Kim, Dong-Wook
    HAEMATOLOGICA, 2014, 99 (07) : 1191 - 1196
  • [27] PREDICTIVE FACTORS FOR OUTCOME TO NOVEL BCR-ABL1 TYROSINE KINASE INHIBITORS IN IMATINIB FAILED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA
    Lee, S. E.
    Choi, S. Y.
    Kim, S. H.
    Oh, Y. J.
    Chae, M. J.
    Song, H. Y.
    Yoo, H. L.
    Lee, M. Y.
    Jang, E. J.
    Jeong, K. H.
    Lee, J. S.
    Kim, D. W.
    HAEMATOLOGICA, 2014, 99 : 336 - 336
  • [28] Brefeldin A Induces Apoptosis, Inhibits BCR-ABL Activation, and Triggers BCR-ABL Degradation in Chronic Myeloid Leukemia K562 Cells
    Zhang, Jin-Man
    Wang, Cui-Fang
    Wei, Mei-Yan
    Dong, Hui
    Gu, Yu-Cheng
    Mo, Xiao-Mei
    Shao, Chang-Lun
    Liu, Ming
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2022, 22 (06) : 1091 - 1101
  • [29] Long-term BCR-ABL1 Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia
    Pinilla-Ibarz, Javier
    Sweet, Kendra
    Emole, Josephine
    Fradley, Michael
    ANTICANCER RESEARCH, 2015, 35 (12) : 6355 - 6364
  • [30] Secondary fusions as a mechanism of BCR-ABL1 kinase-independent resistance in chronic myeloid leukemia
    Barnes, Evan J.
    Eide, Christopher A.
    Bottomly, Daniel
    Wilmot, Beth
    McWeeney, Shannon K.
    Tognon, Cristina E.
    Druker, Brian J.
    CANCER RESEARCH, 2021, 81 (13)
12345